patients were stained for iron and TfR1 protein using Prussian Blue and immunohistochemistry, respectively. 178 tissue cores from 14 different body sites of non-cancer patients were included as controls. Staining was scored by a clinically blinded genitourinary pathologist based on the product of intensity and tissue percentage (Z-score), and tested for association with clinicopathologic features and survival using a MannWhitney U test, Kruskal Wallis test and Cox regression model. RESULTS: Renal epithelium from non-cancer patients had low iron content (mean Z-score, MZS¼ 0.1), but by far the highest TfR1 levels of any tissue site in the body (MZS¼ 153). Compared to non-cancer patients, iron content in RCC patients increased mildly (4-fold) in benign renal epithelium (MZS¼ 0.6) and dramatically (>100 fold) in primary tumors (MZS¼ 21, p< 0.001). Higher tumor iron content was accompanied by moderate TfR1 downregulation (MZS¼ 21, p< 0.001) and associated with clear cell and papillary histologies, male gender and tobacco usage (p< 0.05 each). Opposite to changes observed with tumorigenesis, iron and TfR1 levels decreased and increased, respectively, with progression in tumor size, grade, pT stage and metastatic stage (all p< 0.05). Iron loss and TfR1 upregulation were most apparent in metastatic lesions (MZS¼ 5 and 111, respectively) and each associated with patient anemia and worse RCC-specific survival (all p< 0.05).
INTRODUCTION AND OBJECTIVES: Five-year survival of metastatic renal cell carcinoma (mRCC) patients is < 10% and African American (AA) males have the highest incidence. Identification of the molecular determinants of mRCC and racial disparity in RCC is critical for biomarker development and targeted therapy. SDCT2 expressed in kidney epithelial cells is a succinate/citrate transporter, however its role has not been examined in any disease. We examined SDCT2 expression in normal and RCC tissues and correlated it with clinical outcome and racial disparity. We also evaluated biological functions and molecular signaling regulated by SDCT2 in RCC cells.
METHODS: Differential gene expression in the matched normal and RCC tissues (n¼6/category) was evaluated by microarray analysis; results were validated by QPCR and immunoblotting in tissues from 53 patients (White¼21; Hispanic¼19; AA¼13). VHL+ and VHL-RCC cells were stablely transfected with a SDCT2 construct. Transfectants were characterized for cell proliferation, cell cycle, motility, succinate/citrate transport and reactive oxygen species (ROS) measurement assays under normoxia and hypoxia. SDCT2 induction was evaluated following 5-azacytidine plus Trichostatin A (5-AZA/TSA) treatment.
RESULTS: SDCT2 was 63-and 100-fold downregulated in lowand high-stage RCC tissues. Q-PCR validation showed 40-fold downregulation of SDCT2 in RCC tissues when compared to normal kidney (P< 0.0001). Downregulation was 40-fold in White and Hispanic patients, but 198-fold in AA patients (P¼0.0049) and correlated with tumor stage and metastasis (P¼0.009). Under hypoxia, SDCT2 expression caused 3-4-fold inhibition of proliferation, cell-cycle, motility in both VHL+ and VHL-cells (P<0.01); only VHL+ cells were inhibited under normoxia. SDCT2 expression induced ROS levels and succinate transport by >3-fold (P<0.01) and activated p16INK4a-RB pathway and apoptosis (caspase-3 and PARP activation). 5-AZA+TSA treatment induced SDCT2 expression by 50-fold (P<0.001).
CONCLUSIONS: This is the first study on a functional biomarker in RCC, SDCT2, that is possibly a novel tumor suppressor gene. SDCT2 loss promotes RCC growth, survival and inhibits cellular senescence and its downregulation correlates with metastasis and racial disparity.
Source of Funding: Grant NCI/NIH 5R01CA72821; 5R01CA176691

MP39-16 SERUM TISSUE FACTOR AS A BIOMARKER FOR RENAL CLEAR CELL CARCINOMA
Daniel Silva*, Bartira Pinheiro da Costa, Jorge Antonio Pastro Noronha, Gustavo Carvalhal, Porto Alegre, Brazil
INTRODUCTION AND OBJECTIVES:
We have previously demonstrated that increased expression of Tissue Factor (TF) in tissue samples RCCC is an independent prognostic factor of aggressive behavior and of cancer specific mortality. We aimed to compare preoperative serum TF levels in RCCC patients with those of patients submitted to surgical interventions in patients without RCCC. Additionally, to verify the difference in preoperative and postoperative serum TF levels in RCCC patients in blood samples collected before surgery and after at least four weeks of the surgical procedure.
METHODS: We conducted a prospective study of 30 patients with RCCC submitted to either partial or radical nephrectomy and 16 controls without RCCC treated surgically for other conditions. Serum TF was collected before surgery at the operating room and in the postoperative setting after at least four weeks. Serum samples were analyzed with a commercial ELISA kit for human TF (R&D Systemsâ).
RESULTS: Mean preoperative serum TF levels in RCCC patients and in controls were 66.8 pg/dl and 28.4 pg/dl, respectively (p<0.001). Mean postoperative serum TF levels in RCCC patients were 26.3 pg/dl. In all patients with RCCC postoperative serum levels of TF were lower, with a mean reduction of 41.6 pg/dl in the postoperative setting (p<0.001). Linear regression revealed that tumor size was correlated with the postoperative reduction of serum TF levels (Pearson coefficient ¼ -0.38 ;p¼0.037).
CONCLUSIONS: We have shown a 3-fold reduction in the median preoperative serum levels of TF in patients with RCCC after surgery. We have also shown a difference of the same magnitude in the serum levels of TF compared with those of a control group of patients with benign diseases. TF appears to be a useful serum marker for the presence of RCCC. Further studies are needed to validate these findings. Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e499
